Glycine Cognition Meta-analysis: What the Evidence Says

Quick Answer

Glycine Cognition Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Specifically, these factors encompass social isolation, stigma, substance use, poor dietary habits, and reduced prospects of finding a partner. [Yamada Yuji (2026); evidence level 1]
• Three groups of two investigators (RK, HO, SI, TH, TU, and YY) independently performed a quality assessment using the Cochrane Risk of Bias 2 Tool. [Yamada Yuji (2026); evidence level 1]
• Preclinical and clinical evidence indicate that cisplatin can cross the blood-brain barrier and accumulates in brain regions critical for learning and memory, particularly the hippocampus and prefrontal cortex. [Kazmi Hafiz Muhammad Obaid (2026); evidence level 4]
• These molecular and cellular changes translate into impaired synaptic plasticity, reduced neurogenesis, and deficits in spatial learning and memory on standard behavioral tests,. [Kazmi Hafiz Muhammad Obaid (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For glycine cognition meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Yamada Yuji (2026). Pharmacological interventions for social cognitive impairments in schizophrenia: A systematic review and network meta-analysis of randomized controlled trials. DOI: 10.1192/j.eurpsy.2026.10159. PMCID: PMC13122521. PMID: 41684115. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13122521/
• Kazmi Hafiz Muhammad Obaid (2026). Neuroprotective effects of glycine against cisplatin-induced cognitive decline in mice. DOI: 10.1097/MS9.0000000000004955. PMCID: PMC13236287. PMID: 42254139. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13236287/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.